|
- Trauma Addiction Treatment Recovery
Trauma Addiction Treatment Recovery Trauma is a contributing risk factor in developing substance use disorder Many individuals with substance use disorders use alcohol and other drugs to self-soothe and help decrease symptoms of anxiety, guilt, shame, fear, irritability, anger, insomnia, depression, loss of appetite, and inability to concentrate MANY OF THESE TYPES OF SYMPTOMS ARE
- Initiating extended-release naltrexone for alcohol use disorder in the . . .
Emergency Department (ED) visits are prime opportunities to provide alcohol use disorder intervention and initiate pharmacotherapy This study examined the feasibility of initiating extended-release injectable naltrexone with case management in the ED
- For opioid use disorder patients with more challenges, a tailored . . .
Work to-date suggests individual factors and the intensity of medication management influence treatment response to pharmacotherapy with and without cognitive-behavioral interventions for substance use disorder
- Buprenorphine, but not naltrexone or its extended release version . . .
Pharmacotherapy patients who are younger, prescribed other medications, seeking other addiction treatment services, and have co-occurring substance use disorders may be at increased risk for overdose Additional treatment recovery resources may be needed to help support those with a higher risk of opioid-related overdose
- Harm Reduction – Recovery Research Institute
Visit the post for more Harm Reduction Policies, programs, and practices that aim to reduce the harms associated with the use of alcohol or other drugs Harm reduction is an approach that promotes health in a way that meets people where they are at, accepting that not everyone is ready or capable of stopping their substance use at a given time Instead of making judgments about where
- Smoking interventions can help individuals in addiction treatment quit . . .
The advantages for both pharmacotherapy and pharmacotherapy plus psychosocial approaches were almost 2 times greater for the smoking cessation groups This means that someone would have a 2 times greater likelihood of being abstinent from cigarettes at the last assessment compared to those who received only usual care
- Continuing methadone treatment (versus withdrawal) during a prison term . . .
Ongoing treatment during incarceration may also encourage continued engagement in a methadone treatment program over the year following release, permitting the continued care necessary for optimal recovery outcomes At present, some jails and prisons do not allow individuals to continue pharmacotherapy for opioid use disorder during incarceration
- www. recoveryanswers. org
Integrating Behavioral Therapy with Pharmacotherapy in Treating Patients with Substance Use Disorders, Roger Weiss, M D Medications for Stimulant Use Disorder: Evidence, Infrastructure and Cultural Factors that Support Whole Person Care, Steve Shoptaw, Ph D
|
|
|